With the consent of a majority of its bondholders, Tyco International Ltd. will move ahead with a $250 million settlement putting to rest a lawsuit related to the company's breakup into three separate entities last year.
After failing to get a purported shareholder class action dismissed in March, Taro Pharmaceuticals Ltd. said on Monday that it has reached an agreement with plaintiffs who alleged that the drug company sold excessive amounts of drugs in order to inflate its financial statements.
Three Buchanan Ingersoll & Rooney PC intellectual property litigators, including the head of the firm’s IP practice in California, have joined the ranks of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC.
In a boost to Medtronic Inc., a federal judge has granted the medical device maker's bid to toss an $11 million lawsuit brought by the widow of a man who died after his implantable defibrillator malfunctioned, ruling that she waited too long to bring her claims.
A lawsuit by the U.S. Federal Trade Commission alleging that Cephalon Inc. paid off would-be competitors in the market for its narcolepsy drug Provigil will be heard in Pennsylvania, over the FTC's objections.
The U.S. Food and Drug Administration will adopt new rules for foreign clinical studies used in drug approval applications, including adherence to standards of good clinical practice and approval by an independent ethics committee, the agency said Monday.
The U.S. Patent and Trademark Office has again rebuffed Pfizer Inc.’s bid to reissue one of the patents behind its blockbuster cholesterol drug Lipitor.
In an unusual move, the U.S. Court of Appeals for the Federal Circuit has allowed two friends of the court to participate in oral arguments of a high-profile case that could determine the fate of business method patents.
Unigen Pharmaceuticals Inc., which develops natural, plant-derived products, launched a suit Thursday against Perrigo Company, accusing the store-brand product manufacturer of false advertising and infringing two patents related to popular dietary supplements.
Sanofi-Aventis US LLC, AstraZeneca AB and AT&T Inc. were just some of the companies that hired law firms to work on major IP litigation in recent weeks, according to our daily review of court dockets.
Medtronic Inc. subsidiary Physio-Control said Monday it had brokered a deal with the U.S. Food and Drug Administration over how to improve quality problems related to its external defibrillators more than one year after the company was forced to halt U.S. shipments of the products.
Medical device makers Spectranetics Corp. and Medtronic Inc. have reached a settlement in their ongoing patent dispute over the design of specialized catheters.
The antitrust dispute between the U.S. government and Abbott Laboratories Inc. has devolved into a spat over document production as the company continues to defend itself against allegations that the pharmaceutical industry conspired to artificially boost wholesale drug prices.
The U.S. Food and Drug Administration has asked Congress to consider recommendations for two funding programs for the evaluation of new and generic animal drugs.
Bayer AG is facing 78 lawsuits in the United States over its blood-clotting medication Trasylol, which has been linked to kidney failure and an increased chance of death, the company’s chief executive reportedly told shareholders Friday.
Following in the footsteps of Pfizer Inc.'s Mirapex, a second drug to treat restless leg syndrome has been targeted in a product liability suit, this time Eli Lilly & Co.'s Permax.
Reliant Pharmaceuticals Inc. lost a bid on Thursday to disqualify Frommer Lawrence & Haug LLP from defending Par Pharmaceuticals Inc. in a patent lawsuit over Reliant's heart drug Rythmol SR on the grounds that Frommer Haug had worked with Reliant to acquire the disputed patent.
The plaintiffs in a group of product liability suits over Organon International Inc.'s NuvaRing are pushing for cases concerning the contraceptive device to be consolidated.
The court overseeing a Novartis AG subsidiary's patent infringement suit against Bristol-Myers Squibb Co. and Watson Pharmaceuticals Inc. over the cholesterol-lowering medication pravastatin has signed off on a settlement agreement bringing the case to a close.
The U.S. Food and Drug Administration is not currently able to handle the demands of regulating an increasingly global pharmaceutical supply chain, Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, told a Senate panel Thursday.